skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


Two key marketed drugs, Advair and Symbicort, will face erosion in sales due to the emergence of Breo and other generics emerging from the pipeline. Datamonitor Healthcare has provided an in-depth analysis of key marketed products in the US, Japan, and five major EU markets, including an assessment of product positioning in the face of pipeline competition and an evaluation of clinical and commercial drug attributes.

How will our asthma marketed drugs report benefit you?

  • Gain competitive insight
    Access detailed analyses of key marketed drugs within asthma, including an assessment of product positioning in the face of pipeline competition and an evaluation of commercial and clinical drug attributes to determine competitiveness in the market.
  • Understand market share
    Explore how the emergence of Breo and other generics will affect sales of established drugs such as Advair and Symbicort, allowing you to gain a better understanding of your position within the market.
  • Identify driving forces behind the asthma market
    Examine how novel therapies such as Breo, the first once-daily inhaled corticosteroid/long-acting beta 2 agonist, and Xolair, the only biologic for asthma, are positioned within the market so that you can identify what factors are critical for commercial success.

Key questions answered

  • What clinical trials led to regulatory approval of key marketed brands?
  • What factors will enable marketed brands to resist generic erosion?
  • Will GlaxoSmithKline retain its dominance within the asthma market?

Read also

  • Datamonitor Healthcare: data analysis and insight

    Pharma Must Not Let Its COVID-19 Halo Slip

    By Daniel Chancellor

    Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination.

    Topics Coronavirus $name BioPharmaceutical

  • Datamonitor Healthcare: data analysis and insight, Pink Shee...

    Pharma Intelligence Podcasts

    Listen to the Pharma Intelligence podcasts on Spotify, Apple Podcasts, Soundcloud and Alexa

    Topics Coronavirus $name $name Clinical Trials Blog Clinical Trials Drug Pricing

  • Datamonitor Healthcare: data analysis and insight

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: